256 related articles for article (PubMed ID: 24554924)
1. Pharmacology of the calcium sensing receptor.
Filopanti M; Corbetta S; Barbieri AM; Spada A
Clin Cases Miner Bone Metab; 2013 Sep; 10(3):162-5. PubMed ID: 24554924
[TBL] [Abstract][Full Text] [Related]
2. [Calcimimetics].
Messa P; Como G; Brezzi B
G Ital Nefrol; 2006; 23(1):12-21. PubMed ID: 16521071
[TBL] [Abstract][Full Text] [Related]
3. Calcimimetic and calcilytic drugs for treating bone and mineral-related disorders.
Nemeth EF; Shoback D
Best Pract Res Clin Endocrinol Metab; 2013 Jun; 27(3):373-84. PubMed ID: 23856266
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacological characteristics of drugs targeted on calcium-sensing receptor.-properties of cinacalcet hydrochloride as allosteric modulator].
Nagano N; Tsutsui T
Clin Calcium; 2016 Jun; 26(6):839-50. PubMed ID: 27230839
[TBL] [Abstract][Full Text] [Related]
5. Recent updates on the calcium-sensing receptor as a drug target.
Trivedi R; Mithal A; Chattopadhyay N
Curr Med Chem; 2008; 15(2):178-86. PubMed ID: 18220773
[TBL] [Abstract][Full Text] [Related]
6. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease.
Quarles LD
Kidney Int Suppl; 2005 Jul; (96):S24-8. PubMed ID: 15954947
[TBL] [Abstract][Full Text] [Related]
7. Sensing Extracellular Calcium - An Insight into the Structure and Function of the Calcium-Sensing Receptor (CaSR).
Chavez-Abiega S; Mos I; Centeno PP; Elajnaf T; Schlattl W; Ward DT; Goedhart J; Kallay E
Adv Exp Med Biol; 2020; 1131():1031-1063. PubMed ID: 31646544
[TBL] [Abstract][Full Text] [Related]
8. Calcimimetics and hyperparathyroidism.
Krebs LJ
Curr Opin Investig Drugs; 2004 Oct; 5(10):1080-5. PubMed ID: 15535429
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of calcimimetics targeting the extracellular calcium-sensing receptor (CaSR).
Brown EM
Biochem Pharmacol; 2010 Aug; 80(3):297-307. PubMed ID: 20382129
[TBL] [Abstract][Full Text] [Related]
10. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
11. GENETICS IN ENDOCRINOLOGY: Gain and loss of function mutations of the calcium-sensing receptor and associated proteins: current treatment concepts.
Mayr B; Schnabel D; Dörr HG; Schöfl C
Eur J Endocrinol; 2016 May; 174(5):R189-208. PubMed ID: 26646938
[TBL] [Abstract][Full Text] [Related]
12. MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly.
Filopanti M; Verga U; Ermetici F; Olgiati L; Eller-Vainicher C; Corbetta S; Persani L; Beck-Peccoz P; Spada A
Eur J Endocrinol; 2012 Aug; 167(2):157-64. PubMed ID: 22577108
[TBL] [Abstract][Full Text] [Related]
13. The calcium-sensing receptor in bone metabolism: from bench to bedside and back.
Cianferotti L; Gomes AR; Fabbri S; Tanini A; Brandi ML
Osteoporos Int; 2015 Aug; 26(8):2055-71. PubMed ID: 26100412
[TBL] [Abstract][Full Text] [Related]
14. Calcium-sensing receptor activation in chronic kidney disease: effects beyond parathyroid hormone control.
Massy ZA; Hénaut L; Larsson TE; Vervloet MG
Semin Nephrol; 2014 Nov; 34(6):648-59. PubMed ID: 25498383
[TBL] [Abstract][Full Text] [Related]
15. The role of calcimimetics in the treatment of hyperparathyroidism.
Wüthrich RP; Martin D; Bilezikian JP
Eur J Clin Invest; 2007 Dec; 37(12):915-22. PubMed ID: 18036025
[TBL] [Abstract][Full Text] [Related]
16. Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism.
Kawata T; Imanishi Y; Kobayashi K; Kenko T; Wada M; Ishimura E; Miki T; Nagano N; Inaba M; Arnold A; Nishizawa Y
Eur J Endocrinol; 2005 Oct; 153(4):587-94. PubMed ID: 16189180
[TBL] [Abstract][Full Text] [Related]
17. Extracellular calcium-sensing receptors in the parathyroid gland, kidney, and other tissues.
Quarles LD
Curr Opin Nephrol Hypertens; 2003 Jul; 12(4):349-55. PubMed ID: 12815330
[TBL] [Abstract][Full Text] [Related]
18. Diseases associated with calcium-sensing receptor.
Vahe C; Benomar K; Espiard S; Coppin L; Jannin A; Odou MF; Vantyghem MC
Orphanet J Rare Dis; 2017 Jan; 12(1):19. PubMed ID: 28122587
[TBL] [Abstract][Full Text] [Related]
19. CaSR polymorphism Arg990Gly and response to calcimimetic agents in end-stage kidney disease patients with secondary hyperparathyroidism and in cell culture.
Rothe H; Shapiro W; Sun WY; Matalon A
Per Med; 2008 Mar; 5(2):109-116. PubMed ID: 29783354
[TBL] [Abstract][Full Text] [Related]
20. Molecular and Clinical Aspects of the Target Therapy with the Calcimimetic Cinacalcet in the Treatment of Parathyroid Tumors.
Mingione A; Verdelli C; Terranegra A; Soldati L; Corbetta S
Curr Cancer Drug Targets; 2015; 15(7):563-74. PubMed ID: 26033088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
